Current treatments for GDM, such as lifestyle behavioral change or administration of insulin or metformin, aim to decrease hyperglycemia but do not treat the underlying causes including a sub-optimal β-cell mass (BCM). The gene discussed is INS; the disease is gestational diabetes.